drugset
drugset / Trial / NCT04384081

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

NCT04384081 ↗

Phase 1 Completed 37 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Main objectives are to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of different dose escalation schemes of BI 456906 in healthy Japanese male subject with BMI 23-40 kg/m2 and to determine a dose escalation scheme for future studies.

Timeline

Start
2020-06-01
Primary completion
2020-11-17
Completion
2021-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Survodutide Protein / enzyme biologic — —

Indications

No indication recorded.